Improving anti-HCV therapy.
Copyright policy )Improving anti-HCV therapy.
Hepatitis C virus (HCV) infects about 2% of the world population or approximately 123 million people. The disease causes a significant level of morbidity and mortality among those afflicted. The combination of interferon and ribavirin is effective in many patients. However, the right treatment doses and duration, among other attributes, have a large impact on the treatment outcome.
- Assistance Publique -Hopitaux De Paris France
- Hôpital Cochin France
- Institut Cochin France
- University of Paris France
Dose-Response Relationship, Drug, Interferon Type I, Ribavirin, Humans, Drug Therapy, Combination, Hepatitis C, Chronic, Antiviral Agents, Drug Administration Schedule, Recombinant Proteins
Dose-Response Relationship, Drug, Interferon Type I, Ribavirin, Humans, Drug Therapy, Combination, Hepatitis C, Chronic, Antiviral Agents, Drug Administration Schedule, Recombinant Proteins
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!